- Home
- MS vs AZN Comparison
MS vs AZN Comparison
Compare MS & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MS
- AZN
- Stock Information
- Founded
- MS 1924
- AZN 1992
- Country
- MS United States
- AZN United Kingdom
- Employees
- MS N/A
- AZN N/A
- Industry
- MS Investment Bankers/Brokers/Service
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- MS Finance
- AZN Health Care
- Exchange
- MS Nasdaq
- AZN Nasdaq
- Market Cap
- MS 209.6B
- AZN 228.9B
- IPO Year
- MS N/A
- AZN 1993
- Fundamental
- Price
- MS $140.25
- AZN $69.88
- Analyst Decision
- MS Buy
- AZN Strong Buy
- Analyst Count
- MS 15
- AZN 3
- Target Price
- MS $133.62
- AZN $95.00
- AVG Volume (30 Days)
- MS 5.4M
- AZN 3.7M
- Earning Date
- MS 07-16-2025
- AZN 07-24-2025
- Dividend Yield
- MS 2.63%
- AZN 2.17%
- EPS Growth
- MS 55.47
- AZN 22.71
- EPS
- MS 8.53
- AZN 4.97
- Revenue
- MS $63,959,000,000.00
- AZN $54,982,000,000.00
- Revenue This Year
- MS $10.14
- AZN $9.56
- Revenue Next Year
- MS $4.06
- AZN $6.09
- P/E Ratio
- MS $16.53
- AZN $14.07
- Revenue Growth
- MS 17.42
- AZN 15.48
- 52 Week Low
- MS $90.94
- AZN $61.24
- 52 Week High
- MS $142.03
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- MS 75.29
- AZN 43.21
- Support Level
- MS $130.90
- AZN $69.65
- Resistance Level
- MS $132.80
- AZN $70.37
- Average True Range (ATR)
- MS 2.18
- AZN 0.96
- MACD
- MS 0.49
- AZN -0.41
- Stochastic Oscillator
- MS 96.13
- AZN 7.87
About MS Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments with approximately 45% of net revenue from its institutional securities business, 45% from wealth management, and 10% from investment management. About 24% of its total revenue is from outside the Americas. The company had over $6 trillion of client assets as well as around 70,000 employees at the end of 2024.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.